Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProvexis Regulatory News (PXS)

Share Price Information for Provexis (PXS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.65
Bid: 0.60
Ask: 0.70
Change: 0.00 (0.00%)
Spread: 0.10 (16.667%)
Open: 0.65
High: 0.00
Low: 0.00
Prev. Close: 0.65
PXS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Collaboration agreement

30 Mar 2007 07:02

Provexis PLC30 March 2007 30 March 2007 PROVEXIS PLC ("Provexis" or the "Company") Provexis and Unilever to co-develop Fruitflow(R) technology for application in food products that benefit healthy blood flow Provexis, developer of scientifically-proven functional and medical foods,announces that it has entered into a long-term collaboration agreement withUnilever plc to develop a new format of its patented Fruitflow(R) heart-healthtechnology for application in Unilever's Food product portfolio. Fruitflow(R) is a patented natural extract from tomato which has been shown inhuman trials to reduce the propensity for aberrant blood clotting, typicallyassociated with cardiovascular disease, which can lead to heart attack orstroke. Unilever has substantial global brands in the heart-health market,primarily its Flora/Becel spreads and drinking yoghurts. In 2005 the market forheart benefit foods was worth $4bn globally. Under the terms of the agreement, Provexis and Unilever (the "Partners") willdevelop a second-generation concentrated format of the Fruitflow(R) product forinclusion in Unilever branded products. Subject to clearance of varioustechnical, regulatory and economic issues, the Partners plan to enter into aglobal licence arrangement for the Fruitflow(R) technology. In addition to thedevelopment of the new format, the Partners will also seek to develop other newintellectual property in further related products and processes during thecourse of the collaboration. In the event of a Fruitflow(R) technology licenceagreement not being concluded for any technical, regulatory or economic reason,the collaboration on new intellectual property will continue for a further threeyears. Under the scope of the collaboration agreement and any subsequent licenceagreement, Provexis will grant exclusive rights for certain food and beveragecategories to Unilever, while retaining exclusive global rights to commercialiseFruitflow(R) in drinks (excluding mini-drinks) containing fruit juice; productsmarketed for deep vein thrombosis (DVT), over the counter medicines, medicalfoods, dietary supplements and prescribed medical products. Categories outsideof the exclusive rights granted are available to Unilever on a non-exclusivebasis. Commenting on the signing of the collaboration agreement, Stephen Moon, CEO ofProvexis, said: "This collaboration agreement represents very significant progress in ourextensive joint development work with our partner, Unilever. The joint projectteam is fully engaged in the process of developing the new format and theassociated supply chain, and is making good progress. Given Unilever's strongglobal heart-health brands and the potential licensing revenues flowing from asuccessful collaboration, this is a very important development for Provexis andone which underpins our long-term strategy of discovering, developing andlicensing world-class functional and medical food technologies." Jim Busby, Vice President Unilever Foods R&D (Spreads & Cooking ProductCategory), commented: "Heart-health is and always has been a strong focus area for Unilever. Throughopen innovation agreements like this, Unilever ensures access to the latestscientific and technological advances in heart health. Once we have performedour standard safety and efficacy tests for the application of the tomato extractin our products and we have set up a cost-effective supply chain, we will seekto use this natural heart healthy ingredient in our global Foods portfolio." For further information please contact: Stephen Moon, CEOProvexis plc Tel: 020 8392 6631 Tom Griffiths / Alasdair YounieArbuthnot Securities Tel: 020 7012 2000 END Notes: About Unilever Unilever's mission is to add vitality to life. We meet everyday needs fornutrition, hygiene and personal care with brands that help people feel good,look good and get more out of life. Unilever is one of the world's leading suppliers of fast moving consumer goodswith strong local roots in more than 100 countries across the globe. Itsportfolio includes some of the world's best known and most loved brandsincluding twelve €1 billion brands and global leadership in many categories inwhich the company operates. The portfolio features brand icons such as Flora,Bertolli, Dove, Lux, Pond's, Lynx, Sunsilk, Persil, Cif and Domestos. Unilever has around 179,000 employees in approaching 100 countries and generatedannual sales of €40 billion in 2006. For more information about Unilever and itsbrands, visit www.unilever.com. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
30th Apr 20245:00 pmRNSTotal Voting Rights
28th Mar 20247:00 amRNSIssue of Equity - purchase of Fruitflow® II SD
29th Dec 202312:48 pmRNSHalf-year Report
26th Oct 20231:51 pmRNSResult of AGM
29th Sep 20237:00 amRNSFinal Results
30th Aug 20237:04 amRNSBYHEALTH regulatory filing with Chinese SAMR
3rd Apr 20237:00 amRNSCapital structure and funding update
24th Jan 202311:03 amRNSGrant of Share Options
30th Dec 20228:53 amRNSHalf-year Report
27th Oct 20221:12 pmRNSResult of AGM
14th Oct 20227:00 amRNSDirectorate Change
30th Sep 20227:00 amRNSFinal Results
22nd Jun 20227:00 amRNSTwo new agreements with DSM & patent application
31st May 20225:00 pmRNSTotal Voting Rights
17th May 202212:39 pmRNSExercise of Options and Total Voting Rights
31st Dec 20217:00 amRNSHalf-year Report
26th Nov 20214:41 pmRNSSecond Price Monitoring Extn
26th Nov 20214:36 pmRNSPrice Monitoring Extension
4th Nov 20211:30 pmRNSResult of AGM
4th Nov 202111:07 amRNSBy-Health Fruitflow agreement and support in R&D
1st Oct 20216:04 pmRNSGrant of Share Options
30th Sep 20217:00 amRNSFinal Results
9th Sep 20214:41 pmRNSSecond Price Monitoring Extn
9th Sep 20214:35 pmRNSPrice Monitoring Extension
24th Aug 20214:35 pmRNSPrice Monitoring Extension
22nd Jul 20214:40 pmRNSSecond Price Monitoring Extn
22nd Jul 20214:35 pmRNSPrice Monitoring Extension
21st Jul 20214:41 pmRNSSecond Price Monitoring Extn
21st Jul 20214:36 pmRNSPrice Monitoring Extension
5th Jul 20214:35 pmRNSPrice Monitoring Extension
1st Jul 20214:40 pmRNSSecond Price Monitoring Extn
1st Jul 20214:35 pmRNSPrice Monitoring Extension
26th Feb 20215:00 pmRNSTotal Voting Rights
19th Feb 20217:30 amRNSDirector / PDMR notification
19th Feb 20217:00 amRNSPlacing of new ordinary shares to raise £50,000
29th Jan 202112:37 pmRNSHalf-year Report
31st Dec 20201:00 pmRNSTotal Voting Rights
17th Dec 20207:00 amRNS£1m placing & update re HY results
16th Nov 20207:00 amRNSExclusive Distribution Agreement for Chinese CBEC
30th Oct 20202:09 pmRNSResult of AGM
30th Sep 20207:00 amRNSFinal Results
28th Aug 20205:00 pmRNSTotal Voting Rights
13th Aug 20207:00 amRNSFruitflow® & Blood Pressure - purchase of IP
7th Aug 20205:11 pmRNSHolding(s) in Company
27th May 20207:00 amRNSHolding(s) in Company
31st Dec 20197:13 amRNSInterim Results and Total Voting Rights
11th Dec 20197:00 amRNSPlacing of new ordinary shares to raise £0.301m
4th Oct 20191:19 pmRNSResult of AGM
12th Sep 20193:19 pmRNSDirector/PDMR Shareholding
11th Sep 20194:02 pmRNSGrant of Share Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.